Anthropic wants to disrupt drug discovery. Industry experts say the r…

Anthropic has launched an internal drug discovery initiative using its AI models, but industry experts argue the company is solving only the early-stage discovery problem while ignoring the decade-long, $2.7bn clinical trial phase where 90% of candidates fail. Anthropic is entering drug discovery with enormous capital but solving the wrong problem - molecular screening, not clinical trials. If you're a biotech founder with compounds failing clinical tests, Anthropic's AI won't help you; if you're building tools for trial design, patient matching, or dosage optimisation, you now have a well-funded competitor chasing the early stage instead of the hard stage.